Renzapride
http://dbpedia.org/resource/Renzapride an entity of type: Thing
رينزابرايد (بالإنجليزية: Renzapride) ويعرف بالاسم التجاري رينزابرايد (بالإنجليزية: Renzapride) هو دواء يساعد على تنظيم حركة الأمعاء، ويستخدم لعلاج التهاب المعدة، والارتجاع المعدي المريئي، عسر الهضم، أعراض القولون العصبي.
rdf:langString
Renzapride is a prokinetic agent and antiemetic which acts as a full 5-HT4 agonist and partial 5-HT3 antagonist. It also functions as a 5-HT2B antagonist and has some affinity for the 5-HT2A and 5-HT2C receptors. Renzapride was being developed by Alizyme plc of the United Kingdom. In May 2016, EndoLogic LLC, a US-based pharmaceutical and medical device company, acquired the US and worldwide patent rights to Renzapride. Endologic confirmed the cardiac safety of renzapride through a “Thorough QTc” study and sold the rights to Atlantic Healthcare plc in 2019, a specialist pharmaceutical company.
rdf:langString
rdf:langString
رينزابرايد
rdf:langString
Renzapride
xsd:integer
2239896
xsd:integer
1115979742
rdf:langString
none
xsd:integer
16
xsd:integer
109872
112727
xsd:integer
289753
xsd:integer
16736758
xsd:integer
1
xsd:integer
22
rdf:langString
HCl
xsd:integer
4
xsd:integer
3
xsd:integer
2
xsd:integer
3086547
rdf:langString
Clc1ccCN[C@@H]3CC[N@]2C[C@@H]3CCC2
xsd:integer
1
rdf:langString
GZSKEXSLDPEFPT-IINYFYTJSA-N
xsd:integer
6
9073
rdf:langString
changed
xsd:integer
464380859
rdf:langString
changed
rdf:langString
رينزابرايد (بالإنجليزية: Renzapride) ويعرف بالاسم التجاري رينزابرايد (بالإنجليزية: Renzapride) هو دواء يساعد على تنظيم حركة الأمعاء، ويستخدم لعلاج التهاب المعدة، والارتجاع المعدي المريئي، عسر الهضم، أعراض القولون العصبي.
rdf:langString
Renzapride is a prokinetic agent and antiemetic which acts as a full 5-HT4 agonist and partial 5-HT3 antagonist. It also functions as a 5-HT2B antagonist and has some affinity for the 5-HT2A and 5-HT2C receptors. Renzapride was being developed by Alizyme plc of the United Kingdom. In May 2016, EndoLogic LLC, a US-based pharmaceutical and medical device company, acquired the US and worldwide patent rights to Renzapride. Endologic confirmed the cardiac safety of renzapride through a “Thorough QTc” study and sold the rights to Atlantic Healthcare plc in 2019, a specialist pharmaceutical company. Atlantic Healthcare is focusing on the development of renzapride for the management of gastrointestinal (GI) motility in a number of rare diseases, including systemic scleroderma and cystic fibrosis, both of which are associated with chronic GI motility problems and for which there are no approved therapies.
xsd:integer
244
xsd:nonNegativeInteger
8927
xsd:string
109872-41-5
xsd:string
112727-80-7
xsd:string
289753
xsd:string
6H0SNK4GNT
xsd:string
9073C0W4E9
xsd:string
3086547